Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses.
Abstract: The objective of this study was to determine the pharmacokinetic parameters of oclacitinib maleate as a top dress given to adult horses. Six adult horses with a mean weight of 528 kg were administered a single dose of 0.5 mg/kg oclacitinib maleate. Blood was collected prior to drug administration and at 15 min, 30 min, 45 min, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h after treatment. Oclacitinib maleate plasma concentrations were measured by liquid chromatography/mass spectrometry. Pharmacokinetic parameters were found best to fit a one-compartment model. Mean C was 486 ng/ml (range 423-549 ng/ml), and T was estimated to be 1.7 h (range 0.3-3.1 h). The estimated T was 7.5-8 h.
© 2022 John Wiley & Sons Ltd.
Publication Date: 2022-01-30 PubMed ID: 35098559DOI: 10.1111/jvp.13043Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study examines how a drug called oclacitinib maleate disperses and reacts in the bodies of adult horses after it’s administered in a single dosage.
Study Set Up
The researchers chose six adult horses with an average weight of 528 kilograms for the study. These horses were each given 0.5 milligrams of the drug oclacitinib maleate for every kilogram of their weight:
- This equates to a dosage of about 264 milligrams per horse if each horse weighed exactly the average weight of 528 kilograms.
Procedure
- A blood sample was taken from each horse before administering the drug to establish a baseline.
- Subsequent blood samples were then taken at set intervals – 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours and 72 hours – after the drug was administered.
- The amount of oclacitinib maleate in the plasma of the blood was measured using a process known as liquid chromatography/mass spectrometry. This method separates and identifies the amount and type of chemicals in a solution — in this case, the plasma from the horse’s blood.
Results
- The drug’s rate of dispersion and interaction in the body (its pharmacokinetic parameters) followed a one-compartment model. In pharmacology, a one-compartment model assumes the body acts as a single, unified system where the substance is evenly distributed and eliminated at the same time.
- The average amount of oclacitinib maleate detected in the plasma (C) was 486 nanograms per milliliter, with a range of 423 to 549 nanograms per milliliter.
- The average time it took to reach the peak concentration (T) was calculated to be 1.7 hours, with the actual time varying between 0.3 to 3.1 hours.
- The lifespan of the drug in the body (T), or the time during which the drug is therapeutic without being toxic, is estimated to be between 7.5 to 8 hours.
The findings offer a time-based overview of the journey of oclacitinib maleate in the body of a horse, providing key information on the pharmacokinetics of the drug.
Cite This Article
APA
Hunyadi L, Datta P, Rewers-Felkins K, Sundman E, Hale T, Fajt V, Wagner S.
(2022).
Pharmacokinetics of a single dose of oclacitinib maleate as a top dress in adult horses.
J Vet Pharmacol Ther, 45(3), 320-324.
https://doi.org/10.1111/jvp.13043 Publication
Researcher Affiliations
- School of Veterinary Medicine, Texas Tech University, Amarillo, Texas, USA.
- Health Sciences Center, Infant Risk Center, Texas Tech University, Amarillo, Texas, USA.
- Health Sciences Center, Infant Risk Center, Texas Tech University, Amarillo, Texas, USA.
- School of Veterinary Medicine, Texas Tech University, Amarillo, Texas, USA.
- Health Sciences Center, Infant Risk Center, Texas Tech University, Amarillo, Texas, USA.
- College of Veterinary Medicine & Biomedical Sciences, Texas A & M University, College Station, Texas, USA.
- School of Veterinary Medicine, Texas Tech University, Amarillo, Texas, USA.
MeSH Terms
- Administration, Oral
- Animals
- Area Under Curve
- Chromatography, Liquid / veterinary
- Horses
- Maleates
- Pyrimidines / pharmacokinetics
- Sulfonamides / pharmacokinetics
References
This article includes 11 references
- . Apoquel Freedom of Information Summary. .
- Baker K, Quinn P. A report on clinical aspects and histopathology of sweet itch. Equine Veterinary Journal 10(4), 243-248.
- Barbet JL, Bevier D, Greiner E. Specific immunotherapy in the treatment of Culicoides hypersensitive horses: A double-blind study. Equine Veterinary Journal 22(4), 232-235.
- Broström H, Larsson Å, Troedsson M. Allergic dermatitis (sweet itch) of Icelandic horses in Sweden: An epidemiological study. Equine Veterinary Journal 19(3), 229-236.
- Collard W, Feenstra K, Thorn J. Pharmacokinetics of oclacitinib following oral and intravenous administration to horses. Paper presented at the ACVIM Forum 2020, Virtual.
- Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Veterinary Dermatology 24(6), 587-e142.
- Gonzales A, Bowman J, Fici G, Zhang M, Mann D, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics 37(4), 317-324.
- Noli C, Matricoti I, Schievano C. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. Veterinary Dermatology 30(2), 110-e130.
- Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: Results of a small prospective pilot study of client-owned cats. Veterinary Dermatology 26(4), 235-e52.
- Stepnik CT, Outerbridge CA, White SD, Kass PH. Equine atopic skin disease and response to allergen-specific immunotherapy: A retrospective study at the University of California-Davis (1991-2008). Veterinary Dermatology 23(1), 29-e27.
- Visser M, Cundiff B, King J, Cleaver D, Sture G. Oclacitinib maleate dose determination study in horses with naturally occuring allergic dermatitis. Paper presented at the ACVIM Forum 2020, Virtual.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists